IMTV 014
Alternative Names: IMTV-014Latest Information Update: 18 Sep 2023
At a glance
- Originator Immgenuity
- Class AIDS vaccines; Attenuated vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 29 Aug 2023 Biostax Corp signs a research collaboration agreement with Immgenuity to focus on using naltrexone and JKB 122 with Immgenuity’s IMTV014 both independently and together to achieve remission with HIV patients
- 29 Aug 2023 Immgenuity has patent protection for IMTV 014 in USA, Canada, Japan, Brazil, Australia, Japan and all countries in Europe and several more countries (Immgenuity website, August 2023).
- 29 Aug 2023 Preclinical trials in HIV infections in USA (Parenteral) prior to August 2023